Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sumatriptan succinate
Drug ID BADD_D02099
Description Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.[A179761] Sumatriptan was granted FDA approval on 28 December 1992.[L6805]
Indications and Usage For the treatment of migraine attacks with or without aura.
Marketing Status Prescription; Discontinued
ATC Code N02CC01
DrugBank ID DB00669
KEGG ID D00676
MeSH ID D018170
PubChem ID 59772
TTD Drug ID D0Z6UC
NDC Product Code 55700-093; 47335-276; 55111-292; 16714-797; 65862-148; 0378-5632; 70518-2859; 55111-293; 76420-093; 70518-3179; 68071-4389; 55700-936; 51407-012; 53069-0560; 65862-146; 51407-013; 62756-521; 63187-969; 65862-147; 0093-2014; 0378-5631; 42847-311; 51407-011; 57315-215; 62756-520; 59651-151; 55700-899; 55111-693; 53002-1593; 16714-040; 68788-6769; 52482-010; 62756-730; 68788-9547; 65862-371; 53002-1562; 70518-1184; 68071-3350; 70518-2738; 71205-111; 0245-0809; 53002-2562; 0093-2013; 16714-798; 0378-5630; 62991-3099; 55111-060; 68071-5072; 64679-728; 16714-796; 53002-2592; 65015-864; 50090-1129; 70594-068; 71205-274; 50090-1130; 50090-2144; 68071-4562; 68071-2283; 70518-1183; 50370-0014; 55111-291; 53002-1592; 55700-846; 49574-517; 63187-797; 52932-0727; 60429-994; 63323-273; 67835-5010; 68788-6778; 48087-0075; 49452-7585; 45865-570; 57315-216; 51552-1376; 63187-617; 65015-860; 63187-049; 63187-931; 71205-251; 55700-759; 62331-049; 53104-7581; 50090-5939; 68071-4815; 53002-2593; 63629-8188; 63187-607; 57315-214; 62756-522
Synonyms Sumatriptan | 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide | Sumatriptan Succinate | Succinate, Sumatriptan | GR-43175 | GR 43175 | GR43175 | Imigran
Chemical Information
Molecular Formula C18H27N3O6S
CAS Registry Number 103628-48-4
SMILES CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cytogenetic abnormalityCalcitonin gene-related peptide 1P06881T93509Not Available
Cytogenetic abnormality5-hydroxytryptamine receptor 1FP30939T78656Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Discomfort08.01.08.003--Not Available
Dissociation19.14.01.002--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Drug abuse19.07.02.010--Not Available
Dry mouth07.06.01.002--
Dysaesthesia17.02.06.003--
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dysmenorrhoea21.01.01.002--
Dysphagia07.01.06.003--
Dysphonia17.02.08.004; 22.02.05.005; 19.19.03.002--
Dyspnoea22.02.01.004; 02.01.03.002--
Dystonia17.01.03.001--Not Available
Ear infection11.01.05.001; 04.03.01.006--Not Available
Ear pain04.03.01.003--
Eczema23.03.04.006--
Electrocardiogram abnormal13.14.05.001--Not Available
Emotional disorder19.04.02.005--Not Available
Endometriosis21.07.01.004--Not Available
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Euphoric mood19.04.02.006--
Exophthalmos05.02.02.002; 06.09.04.001--Not Available
Eye haemorrhage24.07.05.002; 06.07.02.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
Facial pain08.01.08.012--
Facial paralysis17.04.03.008--Not Available
Fatigue08.01.01.002--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 10 Pages